 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Agenus
AGEN
conference date: August 8, 2024, @ 5:30 AM Pacific Time
Agenus Readies Comeback with Impressive Botensilimab Data [March 21, 2023, Seeking Alpha]
Agenus' Updated Data Confirms Long-Term Potential [January 24, 2023, Seeking Alpha]
Agenus Multiple Value-Adding Events Ahead [August 18, 2021, Seeking Alpha]
Agenus/Bristol Myers Squibb Deal Makes for a Strong Buy [May 28, 2021, Seeking Alpha]
Older article links are below the conference tables
| 2024 | |||
| Agenus Q1 2024 |
Agenus Q2 2024 |
Agenus Q3 2024 |
|
| May 7, 2024 | August 8, 2024 | Nov. 12, 2024 | |
| 2023 | |||
| Agenus Q1 2023 |
Agenus Q2 2023 |
Agenus Q3 2023 |
Agenus Q4 2023 |
| May 9, 2023 | Aug. 8, 2023 | Nov. 7, 2023 | March 14, 2024 |
| 2022 | |||
| Agenus Q1 2022 |
Agenus Q2 2022 |
Agenus Q3 2022 |
Agenus Q4 2022 |
| May 10, 2022 | Aug. 9, 2022 | Nov. 8, 2022 | March 14, 2023 |
| 2021 | |||
| Agenus Q1 2021 |
Agenus Q2 2021 |
Agenus Q3 2021 |
Agenus Q4 2021 |
| May 6, 2021 | Aug. 9, 2021 | Nov. 9, 2021 | March 1, 2022 |
| 2020 | |||
| Agenus Q1 2020 |
Agenus Q2 2020 |
Agenus Q3 2020 |
Agenus Q4 2020 |
| May 7, 2020 | Aug 6, 2020 | Oct. 29, 2020 | March 15, 2021 |
| 2019 | |||
| Agenus Q1 2019 |
Agenus Q2 2019 |
Agenus Q3 2019 |
Agenus Q4 2019 |
| May 9, 2019 | Aug. 8, 2019 | Nov. 4, 2019 | March 12, 2020 |
2018 |
|||
| Agenus Q4 2018 |
|||
May 7, 2018 |
Aug. 9, 2018 |
Nov. 6, 2018 |
Mar. 14, 2019 |
2017 |
|||
May 4, 2017 |
August 3, 2017 |
Nov. 7, 2017 |
March 15, 2018 |
2016 |
|||
04/28/2016 |
07/28/2016 |
10/27/2016 |
03/09/2017 |
2015 |
|||
04/23/2015 |
07/23/2015 |
10/27/2015 |
03/03/2016 |
2014 |
|||
05/08/2014 |
07/24/2014 |
10/31/2014 |
02/26/2015 |
2013 |
|||
not available |
not available |
||
08/01/2013 |
10/24/2013 |
03/05/2014 |
|
Agenus 1181 New Cancer Response Data Adds To Conviction [April 14, 2021 at Seeking Alpha]
Agenus A Buy On Coming 2021 Data, FDA Filings [March 15, 2021 at Seeking Alpha]
Agenus: A Buy With iNKT Therapy, MK-4830 Milestone [November 13, 2020 at Seeking Alpha]
Agenus First Data From MK-4830: Another Reason To Buy September 23, 2020 @ Seeking Alpha
Agenus 1181 Is A Potential Cancer Game Changer [May 27, 2020 at Seeking Alpha]
Agenus Reveals Improved Cancer Immunotherapy Therapy Results [March 16, 2020 at Seeking Alpha]
Agenus Approaches Stock-Propelling Events August 13, 2020 @ Seeking Alpha
Agenus A Buy For Cancer Therapy Pipeline [February 26, 2020 at Seeking Alpha]
Agenus On A Roll With More Catalysts Ahead [November 19, 2019 at Seeking Alpha]
Agenus Is A Buy Long Term, Despite Short Interest [June 7, 2019 at Seeking Alpha]
Agenus Melts Down With Blockchain [February 26, 2019]
Agenus Illustrates Dilution And Non-Dilution Perils [June 26, 2018]
Agenus Mystery Therapy Indicates Possible Upside [March 19, 2018]
Incyte Buys Agenus Shares at $6, You Can Buy Them Cheaper [February 15, 2017]
Agenus QS-21 Stimulon part of GSK Malaria Vaccine Gets Positive Review in Europe [July 24, 2015 Agenus press release]
Why Agenus Can Continue to Rise After Doubling [May 15, 2015]
Agenus Platforms Provide Many Shots On Commercialization Goal May 13, 2014 at Seeking Alpha
Checkpoint Modulators and Combination Therapies for Cancer May 15, 2014 at The Chairman's Blog
Agenus Positive Phase II Glioblastoma (Brain Cancer) Results [July 1 Agenus press release]
Agenus (AGEN) is a development-stage biotechnology company specializing in immunology and cancer therapies including checkpoint modulators (CPMs).
Agenus web site
Agenus investor relations page
More Analyst Conference Pages:
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.
Copyright 2024 William P. Meyers